Journey Medical Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- BASIS OF PRESENTATION (Policies)
- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

LICENSES/PRODUCTS ACQUIRED (Details)

v3.22.2.2

LICENSES/PRODUCTS ACQUIRED (Details) - USD ($) $ in Millions						3 Months Ended	9 Months Ended
	Nov. 16, 2021	Jun. 29, 2021	May 14, 2021	Mar. 31, 2021	Jul. 29, 2020	Sep. 30, 2022	Sep. 30, 2022
D F D Agreement
LICENSES/PRODUCTS ACQUIRED
Amount payable		$ 10.0
Value of shares to be issued		$ 5.0
Amount payable to fund clinical trials	$ 24.0
Cash payment						$ 2.7	$ 6.5
D F D Agreement \| Contingent Payment Derivative
LICENSES/PRODUCTS ACQUIRED
Unregistered shares issued	545,131
D F D Agreement \| Minimum
LICENSES/PRODUCTS ACQUIRED
Percentage of royalties payable on net sales		10.00%
D F D Agreement \| Maximum
LICENSES/PRODUCTS ACQUIRED
Threshold additional contingent regulatory and commercial milestone payments payable		$ 158.0
Percentage of royalties payable on net sales		20.00%
Asset purchase agreement \| Qbrexza
LICENSES/PRODUCTS ACQUIRED
Age of patients				9 years
Upfront fees			$ 12.5
Milestone payments payable				$ 144.0
Purchase price				$ 12.5
Asset purchase agreement \| Royalty payment percentage for first two years \| Qbrexza
LICENSES/PRODUCTS ACQUIRED
Period of royalty payments				2 years
Asset purchase agreement \| Royalty payment percentage for eight years thereafter \| Qbrexza
LICENSES/PRODUCTS ACQUIRED
Term of royalty				8 years
License and supply agreement With DRL \| Accutane
LICENSES/PRODUCTS ACQUIRED
Threshold additional contingent regulatory and commercial milestone payments payable					$ 1.0
Upfront fees					1.0
Milestone payments payable					4.0
Amount of expense agreed to pay under the agreement					5.0
Contingent amount payable					$ 17.0
Renewable Mutual Agreement Term					10 years
Termination Written Notice Period To Other Party					180 days

- Definition

Age of patients

+ References

No definition available.

+ Details

Name:	derm_AgeOfPatients
Namespace Prefix:	derm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of expense agreed to pay under the agreement.

+ References

No definition available.

+ Details

Name:	derm_AmountOfExpenseAgreedToPayUnderAgreement
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of contingent amount payable under asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementContingentAmountPayable
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of milestone payments to be paid in asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementMilestonePaymentsPayable
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The period of royalty payments in asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementPeriodOfRoyaltyPayments
Namespace Prefix:	derm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of upfront fees paid in asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementUpfrontFees
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of consideration transferred in asset purchase agreement.

+ References

No definition available.

+ Details

Name:	derm_AssetPurchaseAgreementsPurchasePrice
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount payable to fund the clinical trials under the license, collaboration, and assignment agreement.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementAmountPayableToFundClinicalTrials
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash payment for contingent consideration.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementContingentConsiderationCashPayment
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The value of shares to be issued for payment of contingent consideration.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementContingentConsiderationValueOfSharesToBeIssued
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The percentage of royalties payable on net sales under the license, collaboration, and assignment agreement.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementPercentageOfRoyaltiesPayableOnNetSales
Namespace Prefix:	derm_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Threshold additional contingent regulatory and commercial milestone payments payable under the license, collaboration, and assignment agreement.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementThresholdAdditionalContingentRegulatoryAndCommercialMilestonePaymentsPayable
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Total amount payable under the license, collaboration, and assignment agreement.

+ References

No definition available.

+ Details

Name:	derm_LicenseCollaborationAndAssignmentAgreementTotalAmountPayable
Namespace Prefix:	derm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The period of renewable mutual agreement term .

+ References

No definition available.

+ Details

Name:	derm_RenewableMutualAgreementTerm
Namespace Prefix:	derm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Term of royalty

+ References

No definition available.

+ Details

Name:	derm_TermOfRoyalty
Namespace Prefix:	derm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The period of termination written notice to other party. .

+ References

No definition available.

+ Details

Name:	derm_TerminationWrittenNoticePeriodToOtherParty
Namespace Prefix:	derm_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Total number of unregistered common shares of an entity that have been sold or granted to shareholders.

+ References

No definition available.

+ Details

Name:	derm_UnregisteredCommonStockSharesIssued
Namespace Prefix:	derm_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=derm_DFDAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DerivativeInstrumentRiskAxis=derm_ContingentPaymentDerivativeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=derm_AssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=derm_QbrexzaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=derm_RoyaltyPaymentPercentageForFirstTwoYearsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=derm_RoyaltyPaymentPercentageForEightYearsThereafterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=derm_LicenseAndSupplyAgreementWithDrlMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=derm_AccutaneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: